Can Oral Insulin Slow Onset of Type 1 Diabetes in High-Risk Patients?
Can Oral Insulin Slow Onset of Type 1 Diabetes in High-Risk Patients? |
|
Thomas L. Schwenk, MD reviewing Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group. JAMA 2017 Nov 21. Treatment had no effect on diabetes incidence in relatives of patients with type 1 diabetes. In an earlier study, oral insulin did not prevent or delay onset of type 1 diabetes in close relatives of type 1 diabetics, but subgroup analysis suggested a possible benefit in those with higher autoantibody titers (Diabetes Care 2005; 28:1068). To explore this issue, researchers studied 560 nondiabetic first- and second-degree relatives (age range, 3–45 years) of patients with type 1 diabetes. Participants were assessed for diabetes autoantibodies and first-phase insulin release, were sorted into various subgroups, and were randomized to oral insulin (7.5 mg daily) or placebo. The study focused on a subgroup of 389 participants with higher first-phase insulin release. During median follow-up of 2.7 years, annualized rates of type 1 diabetes onset did not differ significantly between insulin and placebo recipients in either the entire cohort or the high-release subgroup. In one subgroup of 55 patients with low first-phase insulin release, insulin conferred a relative reduction in diabetes incidence that was considered to be exploratory for statistical reasons. |
|
|
|
CITATION(S):
|